Nautilus Biotechnology, Inc.
NASDAQ:NAUTBiotechnology
+$0.05 today
- Market cap
- $309.51M
- Beta
- 0.75
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.45
Volume 4.55M
Average 0.40M
NAUT Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Nautilus Biotechnology, Inc.NASDAQ: NAUT
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue declines year over year
Q1 FY2026 cost of revenue of $1.48M fell 9.2% year over year, ahead of the -43.5% change in trailing-twelve-month cost of revenue. Sequentially, it fell 7.1% from the prior quarter. Over 3 fiscal years it compounded at +23.7% a year.
Context
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -9.2% holds above the trailing-twelve-month pace of -43.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 6.47M USD
- Year-over-year change
- +1.8%
- 4-year CAGR
- +22.8%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.47M | +1.8% |
| FY2024 | 2024-12-31 | 6.35M | +11.4% |
| FY2023 | 2023-12-31 | 5.71M | +67.0% |
| FY2022 | 2022-12-31 | 3.42M | +20.2% |
| FY2021 | 2021-12-31 | 2.84M | — |
Cost of Revenue vs competitors
How NAUT compares with its peers on the latest reported figures
- NAUT's LTM Mar 2026 cost of revenue of $6.32M is the 4th highest of the 11 companies compared; the peer median is $1M.
- Its year-over-year change of -43.5% is the 4th highest of 6, against a peer median of +85.4%.
- Over three fiscal years its annual growth of +23.7% compares with a peer median of +13.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.94M | — | — | 77.7% | |
| LTM Mar 2026 | $17.11M | +85.4% | +27.3% | 848.5% | |
| LTM Mar 2026 | $16.18M | -62.1% | -87.7% | 22.8% | |
| LTM Mar 2026 | $6.32M | -43.5% | +23.7% | — | |
| LTM Mar 2026 | $4M | — | — | 8.8% | |
| LTM Mar 2026 | $1.21M | — | — | 1.7% | |
| LTM Mar 2026 | $793.21K | +354.2% | +64.1% | — | |
| LTM Mar 2026 | $27K | — | — | 0.2% | |
ZURAZura Bio Limited | LTM Mar 2026 | $16K | +220.0% | — | — |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $0 | — | — | — |
| LTM Mar 2026 | -$101K | -104.8% | -1.1% | 44.9% | |
| Peer median (excluding NAUT) | $1M | +85.4% | +13.1% | 22.8% | |
Competitors are the stored peer set for NAUT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 2.84M | 3.42M | 5.71M | 6.35M | 6.47M |
| Gross Profit | (2.84M) | (3.42M) | (5.71M) | (6.35M) | (6.47M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 26.51M | 36.46M | 47.25M | 50.48M | 41.11M |
| Selling, General & Admin | 21.15M | 23.75M | 28.9M | 31M | 25.73M |
| Operating Expenses | 47.66M | 60.2M | 70.45M | 75.12M | 60.37M |
| Depreciation & Amortization | 2.84M | 3.42M | 1.85M | 6.35M | 6.47M |
| EBITDA | (47.47M) | (54.51M) | (61.83M) | (64.43M) | (52.54M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (50.5M) | (63.62M) | (76.15M) | (81.48M) | (66.84M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 329K | 5.82M | 12.55M | 10.78M | 7.87M |
| Interest Expense | 0 | 5.82M | 0 | 0 | 0 |
| Other Income / Expenses | 183K | 5.69M | 12.48M | 10.7M | 7.84M |
| Income Before Tax | (50.32M) | (57.92M) | (63.68M) | (70.78M) | (59M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.32M) | (57.92M) | (63.68M) | (70.78M) | (59M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.60) | (0.46) | (0.51) | (0.56) | (0.47) |
| EPS (Diluted) | (0.60) | (0.46) | (0.51) | (0.56) | (0.47) |
| Weighted Avg Shares | 84.46M | 124.59M | 124.92M | 125.43M | 126.26M |
| Weighted Avg Shares (Diluted) | 84.46M | 124.59M | 124.92M | 125.43M | 126.26M |
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
Intrinsic Alpha fair value
Locked
Current Price
$2.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.